roche__tree

Roche’s Tecentriq combo becomes first EU-approved immunotherapy for triple-negative breast cancer

pharmafile | August 30, 2019 | News story | Medical Communications, Sales and Marketing EMA, Europe, Roche, breast cancer, pharma, tecentriq 

Roche has announced the approval of Tecentriq (atezolizumab), in combination with Celgene’s chemotherapy drug Abraxane (nab paclitaxel), by the European Medicines Agency in the treatment of PD-L1-positive, unresectable locally advanced or metastatic triple-negative breast cancer, making it the first immunotherapy regimen available in the continent for this indication.  

The authorisation covers the combo’s use in patients who have not previously received chemotherapy for metastatic disease, and was supported by strong Phase 3 data evidencing an overall survival benefit of seven months compared to placebo plus Abraxane. Additionally, the combo was shown to reduce the risk of disease progression or death by 38% compared to the placebo combo.

Dr Sandra Horning, Roche’s Chief Medical Officer and Head of Global Product Development, commented on the decision: “For the past 30 years, we have been dedicated to transforming the lives of people with breast cancer. Now, we are pleased to build on this foundation with the news that the first immunotherapy treatment for triple-negative breast cancer is available to people in Europe with PD-L1-positive, metastatic triple-negative breast cancer. The European approval of this Tecentriq combination represents a significant step forward in the treatment of this aggressive breast cancer, where the unmet medical need is great.”

Matt Fellows

Related Content

Pharma sees climate disruption as growing supply-chain risk

Nine in ten pharmaceutical companies across the UK and G7 countries expect climate-related disruption to …

AI in pharma: From lab development to patient impact

In the decade to 2025, AI use in vaccine development has increased markedly but is …

EMA selects TrialAssure anonymisation platform for clinical trial documents

TrialAssure has announced that its ANONYMIZE platform has been selected by the European Medicines Agency …

The Gateway to Local Adoption Series

Latest content